Predicting Tumor Response in Rectal Cancer
Author Information
Author(s): Zlobec I, Vuong T, Compton C C, Lugli A, Michel R P, Hayashi S, Jass J R
Primary Institution: Institute of Pathology, University Hospital of Basel
Hypothesis
Can the combined analysis of VEGF and EGFR predict complete tumor response in rectal cancer treated with preoperative radiotherapy?
Conclusion
The combined analysis of VEGF and EGFR is predictive of complete pathologic response in patients undergoing preoperative radiotherapy for rectal cancer.
Supporting Evidence
- Negative VEGF expression is associated with a greater chance of complete tumor response.
- EGFR positivity significantly increases the odds of complete tumor regression.
- The study identified a subgroup of patients with VEGF-positive and EGFR-negative tumors who are resistant to treatment.
Takeaway
Doctors can use certain markers in tumors to guess how well a patient with rectal cancer will respond to treatment before it starts.
Methodology
The study analyzed pretreatment tumor biopsies for immunohistochemical markers and evaluated their association with complete pathologic response using statistical methods.
Potential Biases
Potential biases may arise from the subjective evaluation of immunohistochemical staining by pathologists.
Limitations
The study is limited by its retrospective nature and the specific patient population studied.
Participant Demographics
The study included 104 patients with newly diagnosed invasive, resectable rectal adenocarcinoma, predominantly cT3 stage.
Statistical Information
P-Value
0.009 for VEGF, 0.01 for EGFR
Confidence Interval
0.24 (0.08–0.69) for VEGF, 3.82 (1.37–10.6) for EGFR
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website